Retension medical chief holds 152,980 stock options

The options vest monthly in 1/36 increments, with each vesting date subject to continued service.

Rhea-AI Filing Summary

Retension Pharmaceuticals, Inc. reported that Chief Medical Officer Alison D. Schechter directly holds stock options covering 152,980 shares of common stock, with an exercise price of $2.43 per share and an expiration date of April 30, 2036. The options were granted May 1, 2026, and vest in 1/36 monthly increments, with the first vesting date on March 23, 2026, subject to her continued service on each vesting date.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Schecter Alison D.

Role Chief Medical Officer

Type	Security	Shares	Price	Value
holding	Stock Option (right to buy) F1	--	--	--

Holdings After Transaction: Stock Option (right to buy) — 152,980 contracts (Direct)

Footnotes (1)

1. F1. Granted to the Reporting Person on May 1, 2026. The stock options vest in in 1/36 monthly increments, with the first vesting date on March 23, 2026, subject to the Reporting Person's continued service to the Issuer on each vesting date.

Key Figures

Common shares underlying options: 152,980 shares Exercise price: $2.43 per share Option expiration date: April 30, 2036 +3 more

6 metrics

Common shares underlying options 152,980 shares Direct stock-option holding

Exercise price $2.43 per share Stock options held by Alison D. Schecter

Option expiration date April 30, 2036 Stock options held by Alison D. Schecter

Vesting increments 1/36 monthly increments Subject to continued service on each vesting date

Grant date May 1, 2026 Stock options held by Alison D. Schecter

First vesting date March 23, 2026 Stock options held by Alison D. Schecter

Key Terms

Stock Option (right to buy), exercise price, vesting date

3 terms

Stock Option (right to buy) financial

"Stock Option (right to buy)"

exercise price financial

"Stock options with an exercise price of $2.43 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting date technical

"with the first vesting date on March 23, 2026"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many RTSN options does Chief Medical Officer Alison D. Schecter hold?

Alison D. Schecter directly holds stock options covering 152,980 shares of common stock. The exercise price is $2.43 per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/13/2026 - 08:14 PM EDT Accepted by SEC EDGAR 10/08/2026 - 06:37 PM EDT Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Schecter Alison D.

(Last) (First) (Middle)

1104 WEST BROAD STREET

SUITE 1029

(Street)

FALLS CHURCH VIRGINIA 22046

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
10/08/2026

3. Issuer Name and Ticker or Trading Symbol
Retension Pharmaceuticals, Inc. [ RTSN ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	(1)	04/30/2036	Common Stock	152,980	$2.43	D

Explanation of Responses:

1. Granted to the Reporting Person on May 1, 2026. The stock options vest in in 1/36 monthly increments, with the first vesting date on March 23, 2026, subject to the Reporting Person's continued service to the Issuer on each vesting date.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Alex Schwartz, Attorney-in-fact	10/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)